Weight-loss drug trial results wipe £147bn off Ozempic maker

Ozempic drugmaker Novo Nordisk was once Europe’s most valuable company - George Frey/Reuters Almost £150bn has been wiped off Ozempic drugmaker Novo Nordisk after a trial of its new weight-loss drug fell short of expectations. Shares in the Danish pharmaceutical giant plunged by 15pc on Monday, wiping around €169bn (£147bn) off its market value in just 90 minutes. Trading was briefly halted in Copenhagen as a result of the sharp sell-off, which drove shares to their lowest level since 2021. It came af ...